Currently out of the existing stock ratings of Matthew Keller, 21 are a BUY (100%).
Analyst Matthew Keller, has had 26.19% of price targets met with an average potential upside of 91.53%, reached in 78 days on average.
Matthew Keller has documented 39 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ACXP, Acurx Pharmaceuticals LLC.
Analyst best performing recommendations are on IFRX (INFLARX N.V.).
The best stock recommendation documented was for IFRX (INFLARX N.V.) on 12/30/2025. The price target of $6 was fulfilled within 269 days with a profit of $4.98 (488.24%), with a performance score of 18.15.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 02-Jul-2025
$10
$8.3 (488.24%)
$280.11
2 months 6 days ago
(10-Sep-2026)
0/2 (0%)
$8.06 (415.46%)
Buy Since 05-Dec-2024
$36
8 months 5 days ago
(11-Mar-2026)
5/5 (100%)
$-1.8 (-4.76%)
53
Buy Since 09-Dec-2024
$10.08
$10.08
1 years 5 months 5 days ago
(11-Jun-2025)
3/3 (100%)
$-26.88 (-72.73%)
178
Which stock is Matthew Keller most bullish on?
Which stock is Matthew Keller most reserved on?